Filing Details
- Accession Number:
- 0000880771-16-000175
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2016-08-16 17:28:48
- Reporting Period:
- 2016-08-12
- Filing Date:
- 2016-08-16
- Accepted Time:
- 2016-08-16 17:28:48
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 880771 | Sciclone Pharmaceuticals Inc | SCLN | Pharmaceutical Preparations (2834) | 943116852 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1635264 | Robert King | 950 Tower Lane, Suite 900 Foster City CA 94404 | Svp Of Prod. Dev/Supply Chain | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2016-08-12 | 46,667 | $4.52 | 63,511 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2016-08-12 | 46,667 | $10.41 | 16,844 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2016-08-12 | 2,000 | $0.00 | 18,844 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2016-08-12 | 2,000 | $10.41 | 16,844 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Non-Qualified Stock Options (right to buy) | Disposition | 2016-08-12 | 46,667 | $0.00 | 46,667 | $4.52 |
| Common Stock | Restricted Stock Unit | Acquisiton | 2016-08-12 | 2,000 | $0.00 | 2,000 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 33,333 | 2024-03-14 | No | 4 | M | Direct | |
| 13,000 | No | 4 | M | Direct |
Footnotes
- Includes 4,262 shares purchased under the Issuer's Employee Stock Purchase Plan from February 28, 2015 through May 31, 2016.
- Granted under the Issuer's 2005 Equity Incentive Plan.
- 25% of such shares vest from one year from the date of grant and 2.0833% vests each month thereafter, provided that the Reporting Person continues to be employed by the Issuer.
- Each restricted stock unit represents the contingent right to receive one share of SciClone Pharmaceuticals, Inc.'s common stock.
- Vesting for such RSUs will occur 25% on March 16, 2016, 25% on March 16, 2017, 25% on March 16, 2018, and 25% on March 16, 2019, or on such later date thereafter as the Company's trading window opens, if it is not open on any of such dates, contingent upon the executive's continued employment.
Billionaire Hedge Funds
